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Summary
Background: Oxidized low-density lipoprotein (OxLDL) and remnant lipoprotein play
a crucial role in the development of atherosclerosis. Recently, a novel method for
measuring remnant cholesterol levels (remnant lipoproteins cholesterol homogenous
assay: RemL-C) has been established. However, the correlation between OxLDL and
remnant lipoprotein, including RemL-C, has not been fully investigated.
Methods: We enrolled 25 consecutive patients with documented coronary artery
disease (CAD) and 20 controls. Remnant-like particle cholesterol (RLP-C) and RemL-
C were used to determine the levels of remnant lipoprotein cholesterol. Serum levels
of malondialdehyde-modiﬁed LDL (MDA-LDL) and OxLDL using a monoclonal antibody
DLH3 (OxPC) were used to measure the concentration of circulating OxLDL.
Results: The CAD group had high levels of fasting glucose and glycosylated
hemoglobin (HbA1c), and low levels of high-density lipoprotein cholesterol compared
with the control group. Serum levels of total cholesterol or LDL cholesterol were not
signiﬁcantly different between the two groups. The levels of RemL-C (p = 0.035),
MDA-LDL (p = 0.018), and MDA-LDL/LDL-C (p = 0.036) in the CAD group were signiﬁ-
cantly higher than those in the control group. The levels of RLP-C tended to be higher
in the CAD group than those in the control group (p = 0.096). Positive correlations
were demonstrated between remnant lipoprotein cholesterol and OxLDL (RLP-C and
MDA-LDL/LDL-C, r = 0.45, p = 0.0024, RLP-C and OxPC, r = 0.51, p = 0.0005, RemL-C
and MDA-LDL/LDL-C, r = 0.42, p = 0.0044, RemL-C and OxPC, r = 0.43, p = 0.0043).
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Similar trends were observed in non-diabetic subjects and in subjects without
metabolic syndrome. Positive correlations were also observed between RLP-C and
RemL-C (r = 0.94, p < 0.0001) and between MDA-LDL/LDL-C and OxPC (r = 0.40,
p = 0.0074).
Conclusions: These results suggest that the association between high levels of remnant
lipoprotein cholesterol and high OxLDL levels might be linked to atherogenesis in
patients with CAD.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Co., Ltd., Tokyo, Japan). Serum levels of RLP-C
were measured by widely using an immunoafﬁnity
mixed gel containing anti-apolipoprotein A-1 and© 2008 Japanese Colleg
reserved.
ntroduction
emnant lipoproteins, which are produced by
ydrolysis of chylomicrons and very low-density
ipoproteins, are thought to be atherogenic [1,2].
emnant lipoproteins, not only activate surface
olecules of monocytes and endothelial cells,
ut also induce foam cell formation and prolif-
ration of smooth muscle cells [2]. Indeed, high
evels of remnant-like particles cholesterol (RLP-
) determined by a widely used method, are
onsidered to be a coronary risk factor and a
redictor of cardiovascular events independent of
igh-density lipoprotein (HDL) cholesterol and low-
ensity lipoprotein (LDL) cholesterol in healthy
ubjects and patients with coronary artery disease
CAD) [3—6].
Oxidized low-density lipoprotein (OxLDL) plays
crucial role in atherogenesis via a number
f initiative and accelerative functions, includ-
ng adherence induction between endothelial cells
nd monocytes, recruitment of monocyte-derived
acrophages into the vessel wall, and foam cell
ormation of macrophages [7—9]. Previous reports
ave shown that the level of circulating OxLDL
s a marker for identifying patients with CAD or
oronary spastic angina [10—12], and has a pos-
tive relationship with acute coronary syndromes
13,14]. Moreover, we and other groups demon-
trated that high levels of OxLDL are independent
redictors of future cardiovascular events in appar-
ntly healthy subjects and patients with CAD
15—18].
Until now, several methodologies have been
vailable for determining the levels of remnant
ipoprotein cholesterols as well as circulating OxLDL
8,9,19]. In the present study, we measured the
evels of remnant lipoprotein cholesterols deter-
ined by RLP-C and a recently established methodremnant lipoproteins cholesterol homogenous
ssay: RemL-C), malondialdehyde-modiﬁed (MDA)-
DL, and oxidized phosphatidylcholine (OxPC) in
atients with CAD and control subjects. Moreover,
a
m
T
Re assessed each correlation between remnant
ipoprotein cholesterol and OxLDL in those sub-
ects.
ethods
ubjects
e enrolled 25 consecutive patients who under-
ent diagnostic angiography at Juntendo University
etween August 2006 and October 2006, and 20
ontrols who had no clinical history of CAD and hos-
italization at the same period. All patients had
ocumented CAD deﬁned as more than 50% stenosis
n at least one major coronary artery. Patients with
cute coronary syndrome and/or ongoing conges-
ive heart failure were excluded. Control subjects
ad no abnormal electrocardiographic ﬁnding and
o evidence of coronary ischemia examined by
tress cardiac testing at our outpatient clinic. Sub-
ects who had liver and/or renal dysfunction, or
ere taking medications, including insulin, lipid-
owering drugs, and vitamin E were also excluded.
ll subjects gave written informed consent and the
thical Committee of the Institution approved this
tudy.
lood sampling and biochemical analysis
hole blood samples were drawn after overnight
asting. Serum levels of total cholesterol, triglyc-
ride (TG), HDL cholesterol, and high sensitivity
-reactive protein (hs-CRP), were measured by
tandard methods. LDL cholesterol values were
easured by the direct assay (Sekisui Medicalnti-apolipoprotein B-100 monoclonal antibodies
ethod (JIMRO II, Otsuka Pharmaceutical Co., Ltd.,
okyo, Japan), as previously described [3,20,21].
emL-C, which has recently been established, was
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also employed in this study (Kyowa Medex Co., Ltd.,
Tokyo, Japan). In brief, RemL-C utilizes a selective
solubilizing and degradative method by using sur-
factant and phospholipase-D. After this reaction,
released cholesterol was measured enzymatically
[22]. The levels of malondialdehyde-modiﬁed LDL
(MDA-LDL) recognized by the monoclonal anti-
body, ML25, and OxPC deﬁned by the monoclonal
antibody, DLH3, were measured by enzyme-linked
immunosorbent assay, as we and other groups pre-
viously reported [8,16,17,23,24].
Statistical analysis
Statistical intergroup differences were analyzed by
the Chi-square test and the Student’s t-test. Corre-
lation between the two parameters was determined
by simple linear regression analysis. A value of
p < 0.05 was considered to be signiﬁcant.
Results
Characteristics of the study subjects
The characteristics of the subjects are shown in
Table 1. There was no signiﬁcant difference in body
mass index, prevalence of hypertension, smoking
history, or family history, between the two groups.
The CAD group had a higher prevalence of dia-
betes mellitus (p = 0.012) and metabolic syndrome
(p = 0.005) deﬁned by the Evaluation Committee of
Diagnostic Criteria for Metabolic syndrome [25],
and signiﬁcantly lower levels of HDL cholesterol
(p = 0.003) than the control group. The levels
of fasting glucose and glycosylated hemoglobin
(HbA1c) in the CAD group were signiﬁcantly higher
than in the control group (p = 0.019, p = 0.001,
respectively). Total cholesterol and LDL cholesterol
levels were not signiﬁcantly different between the
two groups.
Comparison of RLP-C, RemL-C, MDA-LDL,
and Ox-PC between the two groups
As shown in Fig. 1, the CAD group had signiﬁcantly
higher levels of RemL-C than the control group
(12.3± 9.0mg/dl vs. 7.4± 5.1mg/dl, p = 0.035).
The level of RLP-C tended to be higher in
the CAD group than that in the control group
(9.1± 8.6mg/dl vs. 5.7± 3.3mg/dl, p = 0.096). As
demonstrated in Fig. 2, the level of MDA-LDL and
the ratio of MDA-LDL to LDL cholesterol (MDA-
LDL/LDL-C) were signiﬁcantly higher than those in
the control group (181± 53 IU/l vs. 147± 36 IU/l,
A
w
(
w
pM. Hiki et al.
= 0.018; 1.36± 0.36 vs. 1.16± 0.21, p = 0.036,
espectively). There was no signiﬁcant differ-
nce of Ox-PC level between the two groups
9.5± 6.9 IU/l vs. 8.0± 2.9 IU/l, p = 0.38).
The levels of RLP-C (6.6± 3.5mg/dl vs. 4.5±
.8mg/dl, p = 0.050) and RemL-C (9.0± 5.2mg/dl
s. 5.9± 3.7mg/dl, p = 0.066) tended to be higher
n the CAD group than in the control group even in
ubjects without metabolic syndrome. The levels of
LP-C (6.9± 3.1mg/dl vs. 5.4± 3.2mg/dl, p = 0.1)
nd RemL-C (9.9± 4.7mg/dl vs. 7.0± 4.9mg/dl,
= 0.085) tended to be higher in the CAD group
han in the control group in subjects without dia-
etes. The levels of MDA-LDL were signiﬁcantly
igher in the CAD group than in the control group
n the subjects without diabetes (193± 61 IU/l vs.
44± 36 IU/l, p = 0.0065).
ssociations between remnant lipoprotein
holesterol and OxLDL
s shown in Fig. 3, the levels of RLP-C were pos-
tively correlated with MDA-LDL/LDL-C (r = 0.45,
= 0.0024) and OxPC (r = 0.51, p = 0.0005) in all
ubjects. The serum levels of RemL-C were also
ositively correlated with MDA-LDL/LDL-C (r = 0.42,
= 0.0044) and OxPC (r = 0.43, p = 0.0043) in all
ubjects. The positive correlations between RLP-
and MDA-LDL/LDL-C (r = 0.43, p = 0.030), RLP-C
nd OxPC (r = 0.53, p = 0.0062), RemL-C and MDA-
DL/LDL-C (r = 0.46, p = 0.019), and RemL-C and
xPC (r = 0.53, p = 0.0059) were also observed
n the CAD group. The trends of positive cor-
elations between RLP-C and MDA-LDL/LDL-C
r = 0.40, p = 0.08), and RemL-C and MDA-LDL/LDL-
(r = 0.31, p = 0.1) were observed in the control
roup.
The positive correlations between levels of RLP-
and OxPC (r = 0.34, p = 0.057), between levels
f RLP-C and MDA-LDL/LDL-C (r = 0.47, p = 0.0048),
etween levels of RemL-C and OxPC (r = 0.32,
= 0.071), and between levels of RemL-C and MDA-
DL/LDL-C (r = 0.42, p = 0.013), were observed in
on-diabetic patients as well as in all subjects
Fig. 4).
orrelations between each measurement ofs demonstrated in Fig. 5, a strong correlation
as observed between RLP-C and RemL-C levels
r = 0.94, p < 0.0001). The MDA-LDL/LDL-C levels
ere positively correlated with OxPC (r = 0.40,
= 0.0074).
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Table 1 Patient characteristics.
Control CAD p-Value
Number 20 25
Age (years) 58± 12 64± 12 0.126
Male (%) 16 (80) 23 (92) 0.239
BMI (kg/m2) 24.5± 4.8 24.6± 2.4 0.935
Hypertension (%) 11 (55) 19 (76) 0.138
Diabetes mellitus (%) 1 (5) 10 (40) 0.012
Metabolic syndrome (%) 3 (15) 14 (56) 0.005
Smokers (%) 10 (50) 16 (64) 0.448
Family history (%) 3 (15) 5 (20) 0.922
Number of diseased vessels
One (%) — 9 (36)
Two (%) — 10 (40)
Three (%) — 6 (24)
Gensini score — 52.9± 48.6
TC (mg/dl) 215± 28 220± 32 0.587
TG (mg/dl) 125± 89 189± 130 0.066
HDL-C (mg/dl) 60± 14 46± 16 0.003
LDL-C (mg/dl) 127± 27 135± 27 0.343
FBS (mg/dl) 99± 12 120± 36 0.019
HbA1c (%) 5.2± 0.5 6.3± 1.2 0.001
hs-CRP (mg/dl) 0.097± 0.152 0.133± 0.118 0.409
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hData are mean± S.D. CAD, coronary artery disease; BMI, body
density lipoprotein cholesterol; LDL-C, low-density lipoprotei
reactive protein.
iscussion
his study demonstrated that: (1) patients with CAD
ad high levels of remnant lipoprotein cholesterol,
specially when measured by RemL-C method; (2)
AD patients had high levels of MDA-LDL; (3) the
erum levels of remnant lipoprotein cholesterol
ere positively correlated with OxLDL, suggesting
hat the association between high levels of remnant
ipoprotein cholesterol and high OxLDL levels might
e linked to atherogenesis in patients with CAD.
w
T
m
o
igure 1 Comparison of serum levels of remnant lipoprotei
AD, coronary artery disease; RLP-C, remnant-like particle-
omogeneous assay-cholesterol.s index; TC, total cholesterol; TG, triglyceride; HDL-C, high-
lesterol; FBS, fasting blood sugar; hs-CRP, high-sensitivity C-
Recent prospective studies and meta-analysis
learly demonstrated that a high level of TG is
n independent predictor for CAD independent of
ther cardiovascular risk factors [6,26—28]. Indeed,
he deterioration of TG-rich lipoproteins, such
s remnant lipoproteins, is frequently observed
n high risk patients for CAD, such as patients
ith metabolic syndrome and/or diabetes [29—31].
herefore, it is important to establish assays for the
easurement of remnant lipoprotein. Four meth-
ds, including ultracentrifugation, polyacrylamide
n cholesterol between the control and the CAD groups:
cholesterol; RemL-C, remnant lipoproteins cholesterol
112 M. Hiki et al.
Figure 2 Comparison of serum levels of OxLDL between the control and the CAD groups: CAD, coronary artery disease;
OxLDL, oxidized low-density lipoprotein; MDA, malondialdehyde; OxPC, oxidized phosphatidylcholine.
Figure 3 Correlations between remnant lipoprotein cholesterol and OxLDL in all subjects: RLP-C, remnant-like
particle-cholesterol; RemL-C, remnant lipoproteins cholesterol homogeneous assay-cholesterol; OxLDL, oxidized low-
density lipoprotein; MDA, malondialdehyde; OxPC, oxidized phosphatidylcholine.
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Figure 4 Correlations between remnant lipoprotein cholesterol and OxLDL in non-diabetic patients: RLP-C, remnant-
like particle-cholesterol; RemL-C, remnant lipoproteins cholesterol homogeneous assay-cholesterol; OxLDL, oxidized
low-density lipoprotein; MDA, malondialdehyde; OxPC, oxidized phosphatidylcholine.
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ike particle-cholesterol; RemL-C, remnant lipoproteins c
ow-density lipoprotein; MDA, malondialdehyde; OxPC, o
el electrophoresis, RLP-C, and automated analysis
f RemL-C, are available for determining remnant
ipoproteins levels. The former two methods have
ome limitations for widespread use in the clini-
al setting, as they are time- and labor-intensive,
omplicated to perform, and are complex to quan-
ify. In contrast, the latter two methods, especially
LP-C, are commonly used to measure remnant
ipoprotein cholesterol. The correlation between
LP-C and RemL-C levels was consistent with the
revious study (r = 0.95) [22], however, serum lev-
ls of RemL-C, but not RLP-C, were signiﬁcantly
m
a
a
tnt lipoprotein cholesterol and OxLDL: RLP-C, remnant-
sterol homogeneous assay-cholesterol; OxLDL, oxidized
ed phosphatidylcholine.
igher in patients with CAD than in the control sub-
ects. One reason for this difference may be due
o the small sample number of the present study.
nother explanation might be derived from the dif-
erence in the method of measurement. The widely
sed RLP-C assay measures cholesterol levels in the
eterogeneous unbound fraction of anti-apoA1 and
nti-apoB-100 antibodies utilizing immuno-afﬁnity
ethodology [3,20,21]. In contrast, the RemL-C
ssay, which can be carried out by an automated
nalyzer, utilizes selective agents, such as surfac-
ant and phospholipase-D, for the determination of
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remnant lipoproteins [22]. The RemL-C assay might
be sensitive enough to identify high-risk subjects,
such as patients with CAD.
Oxidative modiﬁcation of LDL plays a crucial
role in the pathogenesis of initiation and progres-
sion of atherosclerosis [7—9]. Until recently, several
bioassay systems, such as MDA-LDL recognized by
a monoclonal antibody, ML25, OxPC determined by
the monoclonal antibody, DLH3, and OxLDL utilizing
monoclonal antibodies, 4E6 and E06, for the mea-
surement of circulating OxLDL have been developed
[8,19,23,32,33]. In the present study, the serum
levels of MDA-LDL, but not OxPC, were signiﬁcantly
higher in patients with CAD than in the control sub-
jects. This ﬁnding may be caused by the difference
in OxLDL determination measured from the use of
different antibodies. ML25 for detecting MDA rec-
ognizes part of a lipid peroxide product [23], and
DLH3 for determining OxPC levels speciﬁcally rec-
ognizes oxidized phosphatidylcholine [34]. Indeed,
a modest correlation between MDA-LDL and OxPC
levels was observed in this study (Fig. 3). Further
analyses, including a large number of subjects, are
needed to investigate the differences and clinical
signiﬁcance of each method.
The result of positive correlations between rem-
nant lipoprotein cholesterols and OxLDL levels was
a novel ﬁnding in the present study. Although the
precise mechanism of these correlations is uncer-
tain, the following possibilities are raised. Holvoet
et al. reported that metabolic syndrome was asso-
ciated with higher levels of OxLDL [35]. These
authors also demonstrated the OxLDL levels posi-
tively correlated with waist circumstances, serum
TG, insulin, and glucose levels, and were nega-
tively correlated with levels of HDL cholesterol
[35]. This study found positive correlations not only
between body mass index and remnant cholesterol
levels, but also between body mass index and OxLDL
levels in the present subjects (data not shown).
The levels of total cholesterol and LDL cholesterol
in the present study were identical between the
two groups. The features of the current patients
with CAD might be represented by metabolic syn-
drome. It was reported that metabolic syndrome
shows reduced concentrations of antioxidant vita-
mins [36]. In addition, the high levels of small
dense LDL, which is more susceptible to oxidative
stress, appear to be proportional to the degree
of deterioration of TG rich lipoproteins, such as
remnant particles, in metabolic syndrome [37].
However, the results of the present study have
consistency regardless of diabetes or metabolic syn-
drome. Further studies are needed to clarify the
reason of these correlations. Another possibility is
that enhanced oxidative stress could be induced byM. Hiki et al.
ow-grade inﬂammation in subjects with abdomi-
al obesity [38,39]. These indirect mechanisms may
e linked to positive correlations between remnant
ipoprotein cholesterols and OxLDL levels.
The mechanics and kinetics of OxLDL in the
lood stream remain unclear. It is possible that
xLDL might be partly released from atheroscle-
otic plaques in not only the coronary arteries,
ut also in the systemic arteries. The levels of
xLDL correlated with plaque morphology, espe-
ially macrophage-rich plaque [40], and the amount
f OxLDL in the coronary plaque [41]. These
esults suggest that circulating OxLDL may be
eleased from the atherosclerotic lesions. In the
resent study, there were no signiﬁcant associ-
tions between remnant lipoprotein cholesterol,
xLDL, and number of diseased vessels. Then, we
ssessed correlations between remnant lipoprotein
holesterol, OxLDL, and extent of CAD deﬁned
y Gensini score [42]. The levels of OxPC were
ositively correlated with Gensini score. In addi-
ion, the trend of positive associations between
LP-C and Gensini score and between RemL-C and
ensini score were observed in the CAD group (data
ot shown). These results could explain the pos-
ibility that OxLDL might be partly released from
therosclerotic lesions.
There are several limitations to the current
tudy. First, this investigation was a small sample-
ize study. However, this is, to the best of our
nowledge, the ﬁrst report to demonstrate the cor-
elations of remnant lipoprotein cholesterols and
xLDL determined by different measurement meth-
ds. Studies with larger sample sizes are required
o conﬁrm these results. Secondly, the serum lev-
ls of other oxidative and inﬂammatory markers
xcept hsCRP were not measured. It has been pro-
osed that LDL oxidation may be part of local
nd systemic inﬂammatory reaction [43]. Thirdly,
here were no signiﬁcant differences in total or LDL
holesterol between the CAD patients and the con-
rol subjects. Therefore the results of the present
tudy may not be representative of all patients with
AD.
In conclusion, this study showed that the asso-
iation between high levels of remnant lipoprotein
holesterol and high OxLDL levels might be linked
o atherogenesis in patients with CAD.
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